| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aaf138d1e1e2a334d32c6c78450b4851 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2871 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-37 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate |
2018-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b331f57badf720ac70d11574f196a2d0 |
| publicationDate |
2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020147125-A1 |
| titleOfInvention |
Detection of high risk arterial thromboembolic diseases by markers of coagulation and hemostatic activation |
| abstract |
Disclosed herein is a method for identifying patients with cryptogenic stroke or embolic stroke of undetermined source (ESUS) who are at risk for having occult atrial fibrillation, underlying malignancy, and/or recurrent arterial thromboembolic events. Also disclosed is a method for determining who among these patients will benefit from anticoagulants. Also disclosed herein is a method to predict whether the anticoagulant is sufficiently effective to reduce the activated coagulation system in a patient. Also disclosed wherein is a method for identifying patients with cardiovascular and cerebrovascular arterial diseases who have occult atrial fibrillation, underlying but unrecognized malignancy, and/or are at high risk of recurrent arterial thromboembolic events. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2758120-C1 |
| priorityDate |
2017-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |